Rein Therapeutics, Inc RNTX 深 沪
已收盘 01-09 16:00:00 美东时间
1.17
-0.050
-4.10%
华盛通- 最 高1.22
- 今 开1.20
- 成交量 14.74万股
- 最 低 1.13
- 昨 收 1.22
- 总市值 2811.10万
- 52周最高 3.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.02
- 委 比 -84.88%
- 总股本 2402.65万
- 历史最高 309.60
- 量 比 1.42
- 振 幅 7.38%
- 历史最低 1.01
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rein Therapeutics Q3 EPS $(0.21) Beats $(0.23) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 10.64 percent. This is a 22.22 percent increase over losses of $(0.27) per share from
2025-11-14 23:15
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiopathic pulmonary fibrosis treatment LTI-03.
2025-11-04 02:17
Rein Therapeutics shares are trading higher after the company received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
Rein Therapeutics shares are trading higher after the company received FDA clea...
2025-11-03 20:34
Rein Therapeutics Secures Third Pre-Paid Advance
The latest update is out from Rein Therapeutics ( ($RNTX) ). On July 29, 2025, ...
2025-10-25 05:28
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
2025-09-23 09:52
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics announced the publication of new data on LTI-03 in *iScience*, showing its potential as a breakthrough anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). Tested on lung tissue from IPF patients, LTI-03 demonstrated reduction in scarring and inflammation, while avoiding cell damage. Unlike nintedanib, a current standard-of-care drug, LTI-03’s safety profile is strong. These findings support Rein’s Phase 2 RENEW trial,...
2025-09-17 11:30
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 38.2% to $2.86 dur...
2025-09-05 01:05
Brookline Capital Downgrades Rein Therapeutics to Hold
Brookline Capital analyst Kemp Dolliver downgrades Rein Therapeutics (NASDAQ:RNTX) from Buy to Hold.
2025-08-19 22:17
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received UK MHRA approval to initiate a Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. LTI-03 aims to target fibrosis and protect lung regeneration. The RENEW trial will enroll up to 120 global patients to assess safety, tolerability, and efficacy. Initial data expected in 2026.
2025-08-19 12:00
Aileron Therapeutics Q2 EPS $(0.28) Misses $(0.22) Estimate
Aileron Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 37.78 percent increase over losses of $(0.45) per share
2025-08-15 04:14
